 This is a single-centered trial of a group A streptococcal GAS vaccine, StreptAnovaTM, to be performed in Canada. It will be randomized, observer-blinded, and comparator controlled. The study is designed to assess safety and immunogenicity of three doses 0, 1, 6 months of one dosage 600 μg protein in healthy adults 18 through 50 years of age. 